Neogenesis Biotech and Taipei Veterans General Hospital have launched a clinical research partnership, combining medical expertise, cell detection technology, and data analytics to jointly advance the development of precision and smart medicine.

This collaboration focuses on research related to **Solid Tumors**. By utilizing advanced cell detection technology, we are conducting in-depth analyses of immune cell composition, cell function, and the tumor microenvironment. Our goal is to provide comprehensive clinical research data to assist medical teams in gaining a deeper understanding of disease characteristics and treatment responses.

Beyond clinical sample analysis, the research team is continuously building a high-quality clinical database. By integrating cell detection results, clinical information, and research data, we are creating a platform with long-term research value. Standardized data management and analysis workflows not only improve research efficiency but also lay the foundation for future interdisciplinary collaboration.

Moving forward, Neogenesis Biotech will continue to deepen its partnership with Taipei Veterans General Hospital, integrating artificial intelligence (AI) and big data analytics to gradually establish AI-powered cell analysis models. By leveraging machine learning algorithms to analyze vast amounts of cellular data, we aim to enhance the accuracy and efficiency of cell detection, helping physicians gain clinical insights more rapidly and providing more personalized decision support for patient care.

Neogenesis Biotech remains committed to R&D innovation. Together with medical institutions and research partners, we will continue to drive the translation of clinical research findings, accelerate the development of precision medicine, regenerative medicine, and smart healthcare, and create more possibilities for the future of patient care.

‍